ASX:IMU

Imugene Ltd

Market:

ASX

Market Cap:

$263.51 m

Price

0.06 AUD

Change

-1.64%

52 weeks high

0.07

52 weeks low

0.02

08.18

Director Interviews

In brief

Imugene Ltd (ASX:IMU) is listed on the Australian Securities Exchange.

In brief Deep dive Research Latest news Insight Interviews

Deep dive We explore the investor case for growth companies

Imugene progresses towards human studies for PD1-Vaxx treatment by the end of 2020

Imugene Ltd - Imugene progresses towards human studies for its PD1-Vaxx treatment by the end of 2020

Snapshot

The company is well-funded to deliver on commercial and clinical milestones including the development of CF33, PD1-Vaxx and HER-Vaxx treatments.

Watch

Imugene Ltd - Imugene's Leslie Chong says Roth Capital Partners' report is 'great accomplishment'

Small caps Imugene's Leslie Chong says Roth Capital Partners' report is 'great accomplishment'

2 weeks, 5 days ago

Imugene Ltd - Imugene gets green light to start phase-1 clinical trial of new cancer immunotherapy PD-1 Vaxx

Director Interviews Imugene gets green light to start phase-1 clinical trial of new cancer immunotherapy PD-1 Vaxx

on 20/7/20

Imugene Ltd - Imugene receives $4.13 million R&D tax incentive boost for commercial and clinical milestones

Director Interviews Imugene receives $4.13 million R&D tax incentive boost for commercial and clinical milestones

on 12/11/19

Director Interviews Imugene Limited releases new clinical data for HER-Vaxx cancer vaccine study

on 8/7/19

Follow us on:

© Proactive Investors 2020.

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority. Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use.